SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-038756
Filing Date
2024-05-02
Accepted
2024-05-02 08:05:31
Documents
15
Period of Report
2024-05-02
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0204875-8k_protara.htm   iXBRL 8-K 27484
2 PRESS RELEASE DATED MAY 2, 2024, ISSUED BY THE REGISTRANT ea020487501ex99-1_protara.htm EX-99.1 78332
6 GRAPHIC ex99-1_001.jpg GRAPHIC 15822
  Complete submission text file 0001213900-24-038756.txt   314209

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE tara-20240502.xsd EX-101.SCH 3018
4 XBRL LABEL FILE tara-20240502_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE tara-20240502_pre.xml EX-101.PRE 22361
18 EXTRACTED XBRL INSTANCE DOCUMENT ea0204875-8k_protara_htm.xml XML 3691
Mailing Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010 646-844-0337
Protara Therapeutics, Inc. (Filer) CIK: 0001359931 (see all company filings)

IRS No.: 204580525 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36694 | Film No.: 24905418
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)